MedTrace Logo

Safety and Efficacy of ARQ-252 Cream 0.3% in Subjects With Non-Segmental Facial Vitiligo

NCT04811131 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 114

Last updated 2024-07-12

Study results available
· View outcomes & findings →

Summary

This study will assess the safety and efficacy of ARQ-252 cream in combination with NB-UVB phototherapy treatment in individuals with non-segmental facial vitiligo.

Conditions

  • Vitiligo

Interventions

DRUG

ARQ-252 cream 0.3%

ARQ-252 cream 0.3%

DRUG

ARQ-252 Vehicle cream

ARQ-252 Vehicle cream

DEVICE

NB-UVB phototherapy active treatment

NB-UVB phototherapy active treatment

DEVICE

NB-UVB phototherapy sham treatment

NB-UVB phototherapy sham treatment

Sponsors & Collaborators

  • Arcutis Biotherapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • David Berk, MD · Arcutis Biotherapeutics, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-04
Primary Completion
2021-08-09
Completion
2021-08-09
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04811131 on ClinicalTrials.gov